Director at Puma Biotechnology (PBYI) receives 27,000 restricted stock units in equity grant

Rhea-AI Filing Summary

MILLER MICHAEL PATRICK reported acquisition or exercise transactions in this Form 4 filing.

Puma Biotechnology director Michael Patrick Miller received an equity award in the form of restricted stock units. He was granted 27,000 shares of common stock at no cash cost to him, increasing his directly held stake to 81,000 shares after this grant.

The restricted stock units vest in full on the earlier of one year from the grant date or the next annual shareholder meeting, as long as he continues serving the company. This is a compensation-related grant rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MILLER MICHAEL PATRICK

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	27,000	$0.00	--

Holdings After Transaction: Common Stock — 81,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 27,000 shares Grant price per share: $0.00 per share Shares held after grant: 81,000 shares +1 more

4 metrics

RSU grant size 27,000 shares Restricted Stock Units granted to director on reported date

Grant price per share $0.00 per share Stated transaction price for RSU award

Shares held after grant 81,000 shares Total common shares directly held following transaction

Vesting condition Earlier of 1 year or next annual meeting RSUs vest if service with issuer is continued

Key Terms

Restricted Stock Units, annual shareholder meeting, Grant, award, or other acquisition

3 terms

Restricted Stock Units financial

"Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual shareholder meeting financial

"on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting"

A yearly gathering where a company’s owners (shareholders) and its leaders meet to review performance, approve key decisions like electing directors, and vote on issues such as executive pay or major policy changes. Think of it as an annual town hall for people who own part of the business: investors use it to ask questions, influence direction through votes, and gauge management’s plans and transparency, all of which can affect the stock’s outlook.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILLER MICHAEL PATRICK

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BLVD., SUITE 1700

(Street)

LOS ANGELES CALIFORNIA 90024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		27,000	A	$0(1)	81,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.

	/s/ Gordon Esplin as attorney-in-fact for Michael Patrick Miller	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PUMA BIOTECHNOLOGY (PBYI) report for Michael Patrick Miller?

Puma Biotechnology reported that director Michael Patrick Miller received a grant of 27,000 restricted stock units of common stock. This is a compensation-related equity award, not an open-market stock purchase or sale.

How many PBYI shares does Michael Patrick Miller hold after this Form 4 transaction?

Following the grant, Michael Patrick Miller directly holds 81,000 shares of Puma Biotechnology common stock. This total reflects the addition of 27,000 restricted stock units awarded on the reported grant date.

At what price were Michael Patrick Miller’s new PBYI shares granted?

The 27,000 restricted stock units were granted at a stated price of $0.00 per share. This indicates a stock-based compensation award rather than a cash purchase in the open market.

When do Michael Patrick Miller’s PBYI restricted stock units vest?

The restricted stock units vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting. Vesting is conditioned on his continued service with Puma Biotechnology.

Is Michael Patrick Miller’s Form 4 transaction in PBYI a buy or a sale?

The transaction is classified as an acquisition under code A, representing a grant or award of shares. It is not an open-market buy or sell, but part of Puma Biotechnology’s equity compensation.